Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

This study is looking for older patients who have recently been diagnosed with a type of blood cancer called Diffuse Large B-Cell Lymphoma. You might be suitable if your doctors believe you can't have standard strong chemotherapy, perhaps because you are 80 years old or more, or you are 75 or older and have other health issues that make strong chemotherapy too risky.

You would need to have specific types of cells (CD20+) in your lymphoma and the cancer should be at a certain stage (Stage II to IV). Your general health and organ function would be checked by blood tests and other assessments. You also need to have areas of cancer that can be measured, and your doctors will need a sample of your cancer tissue.

There are also reasons why you might not be able to join. For example, if you have a serious active infection like COVID-19, or severe heart problems. Certain past medical treatments or surgeries within a recent timeframe might also mean you can't take part. The study team will review all your medical information carefully to see if this study is right for you.

If you decide to take part in this study, you will be given epcoritamab, either on its own or with lenalidomide. The study involves regular visits to the hospital for check-ups, blood tests, and to receive your treatment. These visits will help doctors monitor how you are doing, track the progress of your cancer, and check for any side effects. You'll have physical examinations and your medical team will ask you about any symptoms you experience. The treatment will continue for a period, and there will be follow-up appointments even after active treatment ends to see how you are doing in the longer term. The total duration of your participation will be explained by the study team.